Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1016/j.cell.2020.06.035 http://scihub22266oqcxt.onion/10.1016/j.cell.2020.06.035 32645327!7321023!32645327     free     free     free Deprecated: Implicit conversion from float 231.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 231.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 231.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 231.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 231.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       Cell 2020 ; 182 (3): 722-733.e11 Nephropedia Template TP {{tp|p=32645327|t=2020. A Universal Design of Betacoronavirus Vaccines against COVID-19, MERS, and SARS |pdf=|usr=}}{{32645327}} gab.com Text A Universal Design of Betacoronavirus Vaccines against COVID-19, MERS, and SARS JO: Cell http://www.kidney.de/pget.php?&tw=1&pmid=32645327 #FOAvip Vaccines are urgently needed to control the ongoing pandemic COVID-19 and previously emerging MERS/SARS caused by coronavirus (CoV) infections. The CoV spike receptor-binding domain (RBD) is an attractive vaccine target but is undermined by limited immunogenicity. We describe a dimeric form of MERS-CoV RBD that overcomes this limitation. The RBD-dimer significantly increased neutralizing antibody (NAb) titers compared to conventional monomeric form and protected mice against MERS-CoV infection. Crystal structure showed RBD-dimer fully exposed dual receptor-binding motifs, the major target for NAbs. Structure-guided design further yielded a stable version of RBD-dimer as a tandem repeat single-chain (RBD-sc-dimer) which retained the vaccine potency. We generalized this strategy to design vaccines against COVID-19 and SARS, achieving 10- to 100-fold enhancement of NAb titers. RBD-sc-dimers in pilot scale production yielded high yields, supporting their scalability for further clinical development. The framework of immunogen design can be universally applied to other beta-CoV vaccines to counter emerging threats. Twit Text FOAVip A Universal Design of Betacoronavirus Vaccines against COVID-19, MERS, and SARS ????Cell http://www.kidney.de/pget.php?&tw=1&pmid=32645327 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=32645327 #FOAvip English Wikipedia <ref>{{Cite pmid|32645327}}</ref> A Universal Design of Betacoronavirus Vaccines against COVID-19, MERS, and SARS #MMPMID32645327 Dai L; Zheng T; Xu K; Han Y; Xu L; Huang E; An Y; Cheng Y; Li S; Liu M; Yang M; Li Y; Cheng H; Yuan Y; Zhang W; Ke C; Wong G; Qi J; Qin C; Yan J; Gao GF Cell 2020[Aug]; 182 (3): 722-733.e11 PMID32645327show ga Vaccines are urgently needed to control the ongoing pandemic COVID-19 and previously emerging MERS/SARS caused by coronavirus (CoV) infections. The CoV spike receptor-binding domain (RBD) is an attractive vaccine target but is undermined by limited immunogenicity. We describe a dimeric form of MERS-CoV RBD that overcomes this limitation. The RBD-dimer significantly increased neutralizing antibody (NAb) titers compared to conventional monomeric form and protected mice against MERS-CoV infection. Crystal structure showed RBD-dimer fully exposed dual receptor-binding motifs, the major target for NAbs. Structure-guided design further yielded a stable version of RBD-dimer as a tandem repeat single-chain (RBD-sc-dimer) which retained the vaccine potency. We generalized this strategy to design vaccines against COVID-19 and SARS, achieving 10- to 100-fold enhancement of NAb titers. RBD-sc-dimers in pilot scale production yielded high yields, supporting their scalability for further clinical development. The framework of immunogen design can be universally applied to other beta-CoV vaccines to counter emerging threats. |*Universal Design[MESH] |Angiotensin-Converting Enzyme 2[MESH] |Animals[MESH] |Antibodies, Neutralizing/immunology[MESH] |Antibodies, Viral/immunology[MESH] |Betacoronavirus/chemistry/*immunology[MESH] |COVID-19[MESH] |COVID-19 Vaccines[MESH] |Cell Line, Tumor[MESH] |Chlorocebus aethiops[MESH] |Coronavirus Infections/*prevention & control/virology[MESH] |HEK293 Cells[MESH] |Humans[MESH] |Mice[MESH] |Mice, Inbred BALB C[MESH] |Middle East Respiratory Syndrome Coronavirus/chemistry/*immunology[MESH] |Pandemics/*prevention & control[MESH] |Peptidyl-Dipeptidase A/genetics/metabolism[MESH] |Pneumonia, Viral/*prevention & control/virology[MESH] |Protein Binding[MESH] |Protein Interaction Domains and Motifs/immunology[MESH] |Receptors, Virus/metabolism[MESH] |SARS-CoV-2[MESH] |Severe acute respiratory syndrome-related coronavirus/chemistry/*immunology[MESH] |Sf9 Cells[MESH] |Specific Pathogen-Free Organisms[MESH] |Spodoptera[MESH] |Transfection[MESH] |Vaccination/methods[MESH] |Vero Cells[MESH]A Universal Design of Betacoronavirus Vaccines against COVID-19, MERS,(epmc).pdf DeepDyve Pubget Overpricing